Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
(Hinzugefügt: 13.05.2022 um 07:56 Uhr)
Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study
(Hinzugefügt: 26.04.2022 um 13:22 Uhr)
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial
(Hinzugefügt: 20.10.2021 um 14:22 Uhr)
Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: a case series
(Hinzugefügt: 29.09.2021 um 09:53 Uhr)
Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies
(Hinzugefügt: 09.06.2021 um 19:34 Uhr)
Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2
(Hinzugefügt: 10.04.2021 um 05:45 Uhr)
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial
(Hinzugefügt: 22.03.2021 um 07:29 Uhr)
Synairgen plc: Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients
(Hinzugefügt: 13.01.2021 um 11:43 Uhr)
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
(Hinzugefügt: 16.12.2020 um 07:56 Uhr)